AstraZeneca Reports 7% Q3 Revenue Growth to $16.21 B
Current overview (not historical)
AstraZeneca released its 2024 third‑quarter earnings, showing a 7% year‑over‑year revenue increase to $16.21 billion and a core earnings‑per‑share of $2.79, surpassing the $2.59 forecast. The company’s oncology segment drove the growth, with a 17% rise in revenue, largely powered by strong sales of key drugs such as Enhertu and Imfinzi. Despite the robust performance in its specialty portfolio, AstraZeneca’s generics business faced intensified competition, which tempered overall margin expansion. The results have prompted a positive market reaction, with the stock climbing 7% following the announcement.
Written with AI from the reporting · updated 10/30/2026
Expand the detailed fact route and sources
Story route
A station-by-station route from the first public evidence onward; every station carries its own evidence and uncertainty.
- 1Unclassified fact stationOct 30, 00:00recorded Oct 31, 04:26single source
阿斯利康Q3营收增长7%至162.1亿美元
Read original source ↗ BeInCryptoReplay this moment in the explorerEvidence & revisions · 1 source records
- Subject：
- astrazeneca
- Action：
- 报告更强于预期的业绩并宣布主要削减成本计划
- Object：
- 财报与削减成本计划
- Occurred (fact side)：
- Oct 30, 00:00
- Published (valid side)：
- Oct 31, 03:46
- First seen (known side)：
- Oct 31, 04:26
Fact stationSingle source · one-sided claimCopy may have been revised later; time replay is bounded. Layer labels group reading only, not causation between layers.
Uncertainty marks flag where to check the sources; they are not proven causation.
Report timeline
Explore every side through dated source reports.
- BeInCryptoRelated fact: single sourceAstraZeneca Shares Surge 7% on Strong Q3 Earnings and Cost‑Cutting Plan
Report first recorded Oct 31, 04:26
AstraZeneca’s stock jumped nearly 7% after the company reported Q3 revenue of $16.21 billion, up 7% year‑over‑year, and core earnings of $2.79 per share, beating expectations of $2.59. Oncology revenue grew 17%, driven by a 35% increase in Enhertu sales and a 26% rise in Imfinzi. The company also announced a restructuring plan that will generate $1.5 billion in annual savings, with up to $2 billion in upfront costs over the next three years, and will reinvest those savings into its pipeline of more than 180 projects. Despite setbacks in some generic‑challenged drugs and halted trials, investors are optimistic that the company’s cancer portfolio can offset revenue losses from older products.
Read original source ↗
Event activity trend
- Latest comparable
- 3
- Comparable peak
- 10Oct 31, 05:00
- 24h change
- -49%
The chart compares consistently observed participants only. Hover or tap to inspect each hour; use arrow keys to move between observations.
Event discussion
Reader opinions are hosted on GitHub Discussions; posting requires a GitHub account. Comments are not verified facts.